Skip to main content

Table 3 Response rates according to RECIST

From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

  Evaluable patients, n (%)
Responder status Cohort 1 Cohort 2
  (n = 9) (n = 10)
ORR 3 (33) 4 (40)
CR 0 0b
PRa 3 (33) 4 (40)
SD ≥7 weeks 3 (33) 3 (30)
Unconfirmed PRa 1 (11) 2 (20)
PD 3 (33) 3 (30)
  1. ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
  2. aOne patient in cohort 1 and two patients in cohort 2 had unconfirmed partial responses and so were included in the SD seven or more weeks response category.
  3. bFollowing data cut-off, one patient in cohort 2 achieved a CR and, as of December 2012, remained in complete radiological remission; no mutation in the BRCA1 and/or BRCA2 genes was identified in this patient by sequencing and multiplex ligation-dependent probe amplification (MLPA).